1	TITLE: Prevalence and impact of oprD mutations in Pseudomonas aeruginosa strains in
2	cystic fibrosis
3	
4	Laura J. Sherrard ^{1,2*} , Bryan A. Wee ^{3,4*} , Christine Duplancic ¹ , Kay A. Ramsay ^{1,5,6} , Keyur A.
5	Dave ^{1,7} , Emma Ballard ¹ , Claire E. Wainwright ^{5,8} , Keith Grimwood ^{9,10} , Hanna E. Sidjabat ¹¹ ,
6	David M. Whiley ^{11,12} , Scott A. Beatson ^{3,13,14} , Timothy J. Kidd ^{+1,3} , Scott C. Bell ^{+1,5,13,15}
7	
8	¹ QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia
9	² Present address: School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, United
10	Kingdom
11	³ School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane,
12	QLD 4072, Australia
13	⁴ Present address: Usher Institute of Population Health Sciences & Informatics, University of
14	Edinburgh, Edinburgh EH16 4UX, United Kingdom
15	⁵ Faculty of Medicine, The University of Queensland, Brisbane, QLD 4006, Australia
16	⁶ Present address: Department of Biochemistry, University of Otago, Dunedin 9016, New
17	Zealand
18	⁷ Present address: Genome stability Laboratory, Cancer and Ageing Research Program,
19	Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland
20	University of Technology, QLD 4102, Australia
21	⁸ Department of Respiratory and Sleep Medicine, Queensland Children's Hospital, Brisbane,
22	QLD 4101, Australia
23	⁹ School of Medicine and Menzies Health Institute Queensland, Griffith University, Gold
24	Coast QLD 4222, Australia

- 25 ¹⁰ Departments of Infectious Diseases and Paediatrics, Gold Coast Health, Gold Coast, QLD
- 26 4215, Australia
- 27 ¹¹ UQ Centre for Clinical Research (UQCCR), The University of Queensland, Brisbane QLD
- 28 4029, Australia
- ¹² Pathology Queensland Central Laboratory, Brisbane, QLD 4006, Australia
- 30 ¹³ Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane
- 31 QLD 4072, Australia
- 32 ¹⁴ Australian Centre for Ecogenomics, The University of Queensland, Brisbane QLD 4072,
- 33 Australia
- ¹⁵ Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, QLD 4032,
- 35 Australia
- 36 * Co-first authors contributing equally to this work.
- 37 † Co-senior authors contributing equally to this work.
- 38
- 39 Corresponding authors: Scott C. Bell, QIMR Berghofer Medical Research Institute,

40 Brisbane, Australia (scott.bell@health.qld.gov.au) and Timothy J. Kidd, School of Chemistry

- 41 and Molecular Biosciences, The University of Queensland, Brisbane, Australia
- 42 (t.m.kidd@uq.edu.au)
- 43
- 44 **Running title:** *P. aeruginosa* AMR and *oprD* sequences
- 45
- 46 Character count: 59,89847
- 48

49 ABSTRACT

50 Defective OprD porins contribute to carbapenem resistance and may be important in 51 *Pseudomonas aeruginosa* adaptation to cystic fibrosis airways. It is unclear whether oprD 52 mutations are fixed in populations of shared strains that are transmitted between patients or 53 whether novel variants arise during infection. We investigated oprD sequences and 54 antimicrobial resistance of two common Australian shared strains, constructed P. aeruginosa 55 mutants with the most common oprD allelic variants and compared characteristics between 56 patients with or without evidence of infection with strains harbouring these variants. Our data 57 show that three independently acquired nonsense mutations arising from a 1-base pair 58 substitution are fixed in strain sub-lineages. These nonsense mutations are likely to contribute 59 to reduced carbapenem susceptibility in the sub-lineages without compromising in vitro 60 fitness. Not only was lung function worse among patients infected with strains harbouring the 61 nonsense mutations than those without, but they also had an increased hazard rate of lung 62 transplantation/death. Our findings further highlight that understanding adaptive changes may 63 help to distinguish patients with greater adverse outcomes despite infection with the same 64 strain.

65

66 Key words: antimicrobial resistance / carbapenems / cystic fibrosis / oprD / Pseudomonas

67 *aeruginosa*

69 **INTRODUCTION**

70 Cystic fibrosis (CF) is a life-shortening autosomal recessive disease resulting in progressive 71 lung damage (Elborn, Ramsey et al., 2016). Lower airway infection with Pseudomonas 72 aeruginosa is common, increases with age and, when chronic infection is established, is 73 associated with increased antimicrobial resistance (AMR) (Murray, Egan et al., 2007). 74 Although diverse *P. aeruginosa* genotypes are ubiquitous in the natural environment, some 75 people with CF are infected with clonally-related strains ("shared stains"), which often 76 display AMR to multiple drugs (Parkins, Somayaji et al., 2018). Shared strains have been 77 identified nationally in Australia with three genotypes prominent: AUST-01, AUST-02 and 78 AUST-06 (the latter two are particularly common in the state of Queensland, Australia) 79 (Kidd, Ramsay et al., 2013).

80

81 Adaptation of *P. aeruginosa* to survive and persist in the CF lower airway microenvironment 82 occurs in the setting of long-term antibiotic selective pressure with the occurrence of 83 substantial intra-strain phenotypical and genotypical population diversity. Genome 84 sequencing studies have demonstrated that certain loci are more prone to mutation than others 85 (e.g. mexZ, gyrA) (Dettman, Rodrigue et al., 2013, Diaz Caballero, Clark et al., 2015, Marvig, 86 Dolce et al., 2015a, Marvig, Johansen et al., 2013, Marvig, Sommer et al., 2015b, Mowat, 87 Paterson et al., 2011, Smith, Buckley et al., 2006, Williams, Evans et al., 2015). However, 88 there is limited information on whether mutations in AMR-related loci are fixed within 89 independent shared strain genotypes or whether novel variants are generally observed in 90 individual patient isolates, suggesting parallel evolution. Identifying differences in adaptive 91 changes in *P. aeruginosa* may help to predict people with CF at the greatest risk of lung

92 function deterioration (Hoffman, Kulasekara et al., 2009, Li, Kosorok et al., 2005, Mayer-

93 Hamblett, Rosenfeld et al., 2014, Tai, Bell et al., 2015a).

94 We have performed a detailed analysis of *oprD* encoding an outer membrane porin, OprD 95 (Porin D or Protein D2 [(Winsor, Griffiths et al., 2016)]), and AMR in a longitudinal 96 collection of shared strains from patients with CF. Polymorphisms in oprD have been 97 detected frequently within, and between, strains in many studies indicating their potential 98 importance in adaptation of *P. aeruginosa* to the CF airways (Greipel, Fischer et al., 2016, 99 Kos, Deraspe et al., 2015, Marvig et al., 2013, Marvig et al., 2015b, Wee, Tai et al., 2018). 100 OprD facilitates diffusion of substrates, such as carbapenems and basic amino acids, across 101 cell membranes. It is well recognised that decreased expression or mutational inactivation of 102 oprD is an important AMR mechanism (Courtois, Caspar et al., 2018, Jaillard, van Belkum et 103 al., 2017, Kos et al., 2015, Strateva & Yordanov, 2009). It has been shown that virulence is 104 enhanced in P. aeruginosa lacking OprD (Skurnik, Roux et al., 2013), demonstrating that 105 mutations at this locus could potentially have consequences for *in vivo* pathogenicity.

106

107 In this study we hypothesised that commonly encountered shared *P. aeruginosa* strains 108 derived from patients with CF harbour loss-of-function *oprD* mutations that: (1) contribute to 109 reduced susceptibility to carbapenems, and (2) could be used as genetic markers to identify a 110 subset of patients at higher risk of an adverse clinical course.

111 **RESULTS**

112 In silico analysis of oprD sequences

The phylogenetic relationship of *oprD* variants is shown in Fig 1A. The wild-type variant of AUST-02 and AUST-06 (1326-bp) is denoted as the variant that is closest to the base of each *oprD* clade. These are highly conserved with only 2 nucleotide differences between the lineages at nucleotide positions 807 (T or C) and 1065 (C or G); their protein sequences are identical (441 amino acids). Fourteen of 114 (12%) isolates had the denoted wild-type variant.

119

120 Conspicuous loss-of-function mutations in *oprD* caused by a 1-bp substitution or a 1-bp 121 insertion or deletion (indel) occurred multiple times in the strain collection. Notably, three 122 independent nonsense mutations caused by a 1-bp substitution were identified in 79/114 123 (69%) isolates from 32/50 (64%) patients; two mutations were exclusive to the AUST-02 124 genotype (oprD c.526G>T or oprD c.748C>T) and one exclusive to AUST-06 (oprD 125 c.956C>A). These SNPs were predicted to result in a truncated protein sequence in silico, 126 with *oprD* c.526G>T (p.E176X), c.748C>T (p.Q250X), and c.956C>A (p.S319X) leading to 127 truncation at amino acids 175, 249 and 318, respectively. All AUST-02 isolates carrying the 128 oprD c.526G>T (p.E176X) variant belong to the M3L7 sub-type, described previously 129 (Sherrard, Tai et al., 2017, Tai et al., 2015a, Wee et al., 2018).

130

Seven independent 1-bp indels resulting in a shift in the reading frame were also identified in a smaller proportion of isolates (n=20/114; 18%) from 10/50 (20%) participants; each of these belong to the AUST-06 genotype. Six indels were predicted *in silico* to result in a truncated protein sequence, with the remaining indel extending the protein length by 31 amino acids to 472 amino acids.

Only two isolates had acquired additional missense mutations AUS925 (*oprD* c.464_465TG>AA, p.L155Q) and AUS899 (*oprD* c.1174A>C, p.N392H), which were each predicted computationally to affect protein function (Choi, Sims et al., 2012). One isolate (AUS901) had an additional synonymous mutation (*oprD* c.1206T>G). Finally, the *oprD* variant of one AUST-02 isolate (AUS426) was disrupted by an insertion sequence (IS) of the IS3 family that is 100% identical to that found in a sequenced plasmid (GenBank: JX469825.1).

144

145 Participants with >1 isolate sequenced, were generally infected with a strain that had an 146 identical oprD variant (n=14/18; 78%). However, four participants (Patient-11, Patient-17, 147 Patient-24 and Patient-37), had multiple oprD variants among their sequenced isolates (Fig 148 1). Based on the core genome phylogeny of AUST-02 and AUST-06 (Fig 1B), nearly all 149 oprD variants emerge from monophyletic clades, which suggests that lineages with specific 150 oprD variants pre-existed in the population before spreading between patients. However, we 151 also observed in isolates from Patient-11 and Patient-37, a scenario where multiple oprD 152 variants had arisen independently from the same lineage (Fig 1B).

153

154 AMR of clinical isolates

155 There were no statistical differences in MICs of the six anti-pseudomonal antimicrobials 156 tested between the AUST-02 (n=63) and AUST-06 (n=51) genotypes (Fig S1A).

157

Given the prevalence of isolates with a nonsense mutation arising from a 1-bp substitution ('target SNPs'; n=79), we decided to focus on characterising their AMR patterns compared to isolates with other ('indel') *oprD* mutations (n=21; frameshift caused by 1-bp indel or

161 disruption by IS) or the denoted wild-type variant (n=14). MIC comparisons are shown in Fig. 162 S1B. Statistically significant differences in MICs were apparent for all antimicrobials except 163 colistin to which 99% of isolates were susceptible (Table I). Isolates with a variant containing 164 a target SNP (100%) or an indel (95%) were highly resistant to impenem (MIC₅₀: >32 mg/L) 165 whereas only one isolate with the wild-type variant (MIC_{50} : 1.5 mg/L) was resistant (Table I). 166 Those with a target SNP also demonstrated greater resistance and had statistically higher 167 MICs for meropenem (all p < 0.001), ceftazidime (p=0.04 or p < 0.001) and ticarcillin-168 clavulanic acid (all p < 0.001) relative to isolates with other variants (Table I). Isolates with a 169 target SNP had higher MICs for tobramycin (p=0.006) compared to isolates with an indel. 170 171 Finally, to indicate if clinical isolates with target SNPs (oprD c.526G>T, p.E176X; oprD 172 c.748C>T, p.Q250X; oprD c.956C>A' p.S319X) had similar AMR profiles, their MICs were

173 compared. Although MICs did not differ for the carbapenems, they varied statistically for the

174 remaining four antimicrobials tested (Fig S1C).

175

176 Allelic replacement of *oprD* in PAO1

177 Next, we investigated the specific contribution that each target SNP had on carbapenem 178 resistance profiles using PAO1, which is susceptible to imipenem (MIC 1 mg/L) and 179 meropenem (MIC 0.38 mg/L).

180

Introduction of the observed 1-bp substitutions into *oprD* of PAO1 *via* allelic replacement led
to imipenem resistance for all isogenic mutants (PAO1-OprD^{E176X}, 32 mg/L; PAO1OprD^{Q250X}, 24 mg/L; PAO1-OprD^{S319X}, 32 mg/L) and increased the meropenem MIC by ~2-3
doubling dilutions (PAO1-OprD^{E176X}, 3 mg/L; PAO1-OprD^{Q250X}, 2 mg/L; PAO1-OprD^{S319X},
1.5 mg/L).

186 The meropenem MICs are much lower than the MICs seen in the clinical isolates (MIC₅₀: 187 >32 mg/L). All complemented mutants had MICs at wild-type PAO1 levels (Table II). 188 Furthermore, there were no apparent differences in the susceptibility of each isogenic mutant 189 to ceftazidime, ticarcillin-clavulanate, tobramycin and colistin compared to the wild-type 190 strain (Table II).

191

192 It was predicted in silico that each of the target SNPs would lead to a truncated protein of 193 between 175 and 318 amino acids. A global data-dependent liquid chromatography-mass spectrometry analysis found no evidence of OprD protein in the PAO1-OprD^{E176X}, PAO1-194 OprD^{Q250X}, and PAO1-OprD^{S319X} isogenic mutants. In contrast, peptides spanning both N-195 196 and C-terminal regions of the OprD protein were detected in PAO1 and all of the 197 complemented mutants. Targeted mass spectrometry using parallel reaction monitoring 198 (PRM) analysis confirmed these results using tryptic peptides that were unique to OprD when 199 compared to the background proteome of PAO1. Finally, in vitro growth was not affected by 200 the introduction of the target oprD SNPs into the chromosome of PAO1 (Fig S2).

201 Clinical course

- 202 Variant-specific PCR indicated that 434/890 (49%) isolates from 149 participants had one of
- the target SNPs in *oprD* (Fig 2).
- 204

205 Overall, 83/149 (56%) participants were infected with ≥ 1 isolate carrying a target SNP in 206 oprD (Fig 2); whereas the remaining participants (control subjects) had infection with 207 isolates with other oprD variants. Specifically, 101/569 (18%; 22 participants) and 154/569 208 (27%; 27 participants) AUST-02 isolates tested positive for the oprD c.526G>T (p.E176X) 209 and oprD c.748C>T (p.O250X) variants, respectively. All AUST-02 isolates positive for the 210 oprD c.526G>T (p.E176X) variant were confirmed as belonging to the M3L7 sub-type by 211 PCR. More than half (n=179/321, 56%; 41 participants) of AUST-06 isolates tested positive 212 for the oprD c.956C>A (p.S319X) variant. Seven (5%) participants with >1 isolate had 213 multiple target variants detected in concurrent or longitudinal isolates.

214

215 Cases (n=82, one case lacked clinical data and was excluded from the analysis) and control 216 (n=66) subjects were similar with respect to age, sex, CFTR function, chronic/type of shared 217 strain infection status and co-morbidities. The odds of being a case was reduced with higher 218 lung function (OR, 0.97; 95% CI, 0.96-0.99; p<0.001) and increased with a greater number of 219 hospital days (OR, 1.01, 95% CI, 1.00-1.03; p=0.010). Although not statistically significant, 220 the odds of being a case was reduced with increasing BMI (OR, 0.92, 95% CI, 0.83-1.02; 221 p=0.11). Amongst long-term treatments prescribed, inhaled colistin significantly increased 222 the odds of being a case (OR, 2.48, 95% CI, 1.22-5.04; p=0.010) compared to non-inhalation 223 as did tobramycin although it was not significant (OR, 2.13, 95% CI, 0.84-5.43; p=0.11) 224 (Table III). After controlling for all these factors in a multivariable logistic regression, only 225 lung function remained statistically significant.

226

Furthermore, 45/148 (30%; one participant lacked clinical data and was excluded from the analysis) participants were deceased (n=15) or had received a lung transplant (n=30) by the censor date (Table SI). The type of shared strain infection was not found to be predictive of transplant or death (p=0.77). However, being a case had a higher risk of transplant or death (HR, 2.44; 95% CI, 1.27-4.68) compared to being a control subject.

232

233 **DISCUSSION**

234 The emergence of AMR in bacterial pathogens is a foremost concern for clinical management 235 of people with CF, especially as longevity is increasing, and complex antimicrobial treatment 236 regimens are a mainstay of routine care (Waters, Kidd et al., 2019). This study focused on 237 carbapenems, which are fundamental antimicrobials used intravenously to treat pulmonary 238 exacerbations but are often reserved for those with advanced disease or where there is a 239 suboptimal clinical response to other β -lactam antibiotics. Therefore, they are a critical class 240 of antimicrobials to manage the most vulnerable patients. Nevertheless, reduced 241 susceptibility of *P. aeruginosa* to carbapenems is reported, including in our Queensland CF 242 population (Smith, Ramsay et al., 2016, Tai, Kidd et al., 2015b); but the underlying resistance 243 mechanisms and the potential clinical implications of their identification are less clear.

244

In our initial work, we performed a targeted analysis of the *oprD* locus of two major Australian shared strains. We found that both strains frequently carry *oprD* variants, supporting previous studies that identified this gene as a common target for mutation during persistent infection of the CF airways (Greipel et al., 2016, Marvig et al., 2015b). The *oprD* variants identified were not shared by AUST-02 and AUST-06, providing no current evidence of DNA transfer of a variant between the genotypes, even though some patients

251 may be concurrently infected with both strains (Tai, Sherrard et al., 2017). Furthermore, 252 rather than identifying many novel oprD variants that were generally exclusive to individual 253 patient isolates, we repeatedly identified three specific variants in isolates from multiple 254 patients, which were characteristic of monophyletic strain sub-lineages (Fig 1B). Each variant 255 was truncated due to a nonsense mutation caused by a SNP. We hypothesise that these SNPs 256 became fixed in the sub-lineages following their divergence from all other AUST-02/AUST-257 06 strains and these sub-lineages were subsequently disseminated between patients, possibly 258 from patient socialisation or via the aerosol mode of transmission (Knibbs, Johnson et al., 259 2014, Ojenivi, Frederiksen et al., 2000). This is supported by finding that all AUST-02 260 isolates positive by PCR for the oprD c.526G>T (p.E176X) variant were confirmed as 261 belonging to the recently characterised AUST-02 sub-lineage, M3L7, and provides further 262 evidence that this mutation is exclusive to the lineage (Wee et al., 2018). In addition, 263 introduction of the various SNPs of interest into oprD of PAO1 had no impact on in vitro 264 growth suggesting that these mutations may be acquired without a cost to fitness. Acquiring 265 mutations without a fitness cost may further substantiate the likelihood of clinical strains 266 carrying these oprD variants successfully spreading and establishing new infections in the CF 267 patient population (MacLean & San Millan, 2019).

268

Interestingly, we also observed two cases where a single AUST-06 lineage acquired two or three different *oprD* variants within a patient (Fig 1B). It is unclear whether these variants were already present in the AUST-06 population before the patient was infected or whether each variant arose independently during the course of infection.

273

It is reported that reduced expression or inactivation of OprD constitutes a major resistance
mechanism to carbapenems (Courtois et al., 2018, Li, Luo et al., 2012, Llanes, Pourcel et al.,

276 2013) and in keeping with this, our analysis revealed that 99% of imipenem-resistant isolates 277 harboured *oprD* with either a nonsense or indel mutation or on one occasion, disruption by an 278 insertion sequence (MIC₅₀: >32mg/L). Conversely, a full-length coding sequence was 279 associated with much lower MICs (MIC₅₀: 1.5mg/L). One clear discrepancy was a single 280 isolate (AUS396) carrying a 1-bp insertion in oprD between nucleotides at positions 1199 281 and 1200, which was susceptible to imipenem (MIC: 2mg/L). This frameshift mutation was 282 predicted to extend the length of the protein and indeed an earlier study found that isolates 283 carrying additional amino acids at the C-terminus of OprD remained susceptible to 284 carbapenems (Ocampo-Sosa, Cabot et al., 2012). However, three other isolates (AUS886, 285 AUS916, AUS918) carrying the same 1-bp insertion as AUS396 showed resistance to 286 imipenem (MICs: >32mg/L). This highlights the complexity of deciphering the development 287 of AMR and the need for studies characterising the impact of individual and combinations of 288 chromosomally acquired mutations.

289

290 The impact of the various mutations on porin integrity is influenced by their position in the 291 protein sequence (Epp, Kohler et al., 2001, Huang, Jeanteur et al., 1995, Ocampo-Sosa et al., 292 2012). We determined the effect of the three most common oprD SNPs in our strain 293 collection using site-directed mutagenesis in the reference strain, PAO1. Our results showed 294 imipenem resistance and an apparent loss of the porin for all three truncations (p.E176X, 295 p.Q250X, p.S319X). Although 97% of clinical isolates with the target SNPs also had a 296 meropenem MIC >32mg/L, we found that in our isogenic mutants the target SNPs increased 297 the meropenem MIC only by several fold to a maximum of 3 mg/L. It is recognised that 298 mutations in oprD alone do not cause meropenem resistance (Strateva & Yordanov, 2009). 299 The target *oprD* variants are likely to contribute to reduced susceptibility to meropenem in 300 the clinical isolates and clinical resistance may be a polygenic trait. More genetically diverse

301 collections of isolates with meropenem resistance are needed to identify the genes that are 302 significantly associated with this phenotype. Additionally, the SNPs did not impact the MICs 303 of other β -lactam antibiotics, tobramycin or collistin confirming that these mutations 304 specifically affect the activity of carbapenem antibiotics.

305

306 Based on our prior genome sequencing studies of the M3L7 sub-lineage (Sherrard et al., 307 2017, Wee et al., 2018), it is likely that the individual clinical isolates included in the current 308 study harbor a multitude of concurrent mutational mechanisms to achieve the high-level 309 resistance observed to carbapenems and the other antimicrobials studied. Carbapenem 310 resistance can arise from the production of antibiotic-inactivating carbapenemases; but recent 311 studies failed to detect acquired carbapenemase encoding genes in CF P. aeruginosa isolates 312 suggesting that, to date, this mechanism is uncommon in CF (Chalhoub, Saenz et al., 2016, 313 Courtois et al., 2018, Mustafa, Chalhoub et al., 2016, Tai et al., 2015b). Upregulation of 314 multi-drug efflux pumps and de-repression of the cephalosporinase, AmpC, harbouring 315 spectrum-extending mutations may also contribute to increased MICs (Rodriguez-Martinez, 316 Poirel et al., 2009, Strateva & Yordanov, 2009). We previously identified mutations in 317 various efflux pump regulators (e.g. mexZ, nalC, nalD) and pump proteins (e.g. mexX, mexY) 318 and ampC which might also contribute to carbapenem resistance in M3L7 (Sherrard et al., 319 2017). It was proposed that inactivation of OprD could be the primary resistance mechanism 320 induced by carbapenem selective pressure with further mechanisms acquired thereafter (Li et 321 al., 2012).

322

The AUST-02 and AUST-06 genotypes, have been associated with increased treatment requirements compared to unique *P. aeruginosa* genotypes (Kidd et al., 2013). Prior studies have also identified that adaptive mutations in specific loci, including in *mucA* or related

326 genes that lead to mucoidy or loss-of-function mutations in the transcriptional regulator of 327 quorum sensing *lasR* were associated with accelerated decline in lung function or disease 328 progression (Hoffman et al., 2009, Li et al., 2005). In our current work, we identified a subset 329 of people (>50%) infected with AUST-02/AUST-06 with poorer clinical outcomes based on 330 detection of specific oprD variants. This finding extends our previous work that identified a 331 small group of adults infected with M3L7 who had a greater 3-year risk of lung 332 transplantation/death (Tai et al., 2015a) and further highlights the heterogenous clinical 333 course of people despite infection with clonally-related strains. When we investigated the 334 characteristics of people who had acquired strains carrying the target oprD SNPs in our 335 multivariable model, lower forced expiratory volume in one-second % predicted was 336 potentially important. As we are unable to precisely determine when each person first became 337 infected with these strains, it is unknown whether they contribute to lung function decline or 338 alternatively, if certain individuals were at greater risk of their acquisition e.g. from spending 339 more time in hospital; a statistically significant variable in the univariable analysis. 340 Moreover, we found a relationship between people infected with a strain carrying a target 341 oprD SNP and subsequent increased hazard rate of lung transplantation or death; but this also 342 does establish Other studies of not causality. 343 P. aeruginosa blood stream infections have reported that loss of OprD is associated with 344 mortality (Fluit, Rentenaar et al., 2019, Yoon, Kim et al., 2019).

345

A recent study showed that *P. aeruginosa* PA14 transposon *oprD* mutants were carbapenem resistant, and also had enhanced serum resistance and survival in a low pH environment and cytotoxicity against phagocytes in a murine model, which possibly occurred *via* alteration of expression of other genes (Skurnik et al., 2013). Therefore, further work is required to characterise if the target *oprD* SNPs identified in our study also lead to the emergence of

351 more virulent CF sub-lineages with enhanced survival in the acidified airway surface liquid

that is characteristic of the CF lungs (Pezzulo, Tang et al., 2012).

353

354 Limitations of this study include the small number of isolates that were available per person, 355 especially as infection with multiple strain types and co-existence of divergent strain sub-356 lineages is recognised (Diaz Caballero et al., 2015, Tai et al., 2017, Williams et al., 2015). 357 Therefore, we may have underestimated the proportion of people infected with strains 358 carrying the target variants. In addition, the variant-specific PCRs were specific to the SNPs 359 of interest and therefore, only have a potential prognostic value to patient populations where 360 AUST-02 and AUST-06 genotypes have been identified. Furthermore, it is likely that the 361 proportion of isolates, which were negative for the target SNPs, will harbour other loss-of-362 function oprD mutations. If these mutations have similar features to the target SNPs is 363 unclear. It is also unknown if the oprD SNPs identified have a therapeutic value in predicting 364 response to pulmonary exacerbation treatment regimens containing carbapenems. Currently, 365 in vitro AMR and in vivo response to treatment are not well correlated in chronic P. 366 aeruginosa infection (Somayaji, Parkins et al., 2019). Finally, we were unable to exchange 367 the oprD variant carrying a nonsense mutation in AUST-02 or AUST-06 clinical isolates with 368 that of the wild-type variant, as the clinical isolates were insensitive to SacB-mediated 369 sucrose toxicity used for counter selection.

370

371 CONCLUSIONS

We found that nucleotide substitutions and indels were commonly encountered in the *oprD* gene of two prevalent shared strains in an Australian CF population and included three independently acquired nonsense mutations fixed in different sub-lineages. These nonsense mutations could largely explain imipenem resistance amongst the corresponding CF isolates

376	and may be a marker of worse patient outcomes. Studying genes under strong selection
377	pressure, such as oprD, in detail may help improve our understanding of chronic-stage
378	adaptions that contribute to strain transmissibility and greater adverse patient outcomes
379	observed in some people.
380	

381 MATERIALS AND METHODS

382 Clinical isolates

- 383 To account for potential diversity in AMR in vitro and oprD sequences, two shared strains,
- 384 AUST-02 and AUST-06, were selected for this study. All isolates were obtained by prior
- surveillance studies between 2001-2014 (Kidd et al., 2013, O'Carroll, Syrmis et al., 2004,
- 386 Ramsay, Bell et al., 2016, Sherrard et al., 2017) from single colony sputum cultures and were
- 387 identified as AUST-02 or AUST-06 via ERIC-PCR and/or iPLEX20SNP genotyping (Kidd et
- al., 2013, Kidd, Ramsay et al., 2015, O'Carroll et al., 2004, Ramsay et al., 2016, Sherrard et
- al., 2017, Syrmis, Kidd et al., 2014). Isolates are held in the QIMR Berghofer Pseudomonas

390 Biobank.

391

392 Ethics approval

Ethics approval was granted under HREC/07/QRCH/9 and HREC/13/QPCH/127 by The
Prince Charles Hospital (TPCH) Human and Research Ethics Committee. All participants
provided written, informed consent/assent.

396

397 Whole genome analysis

398 Genomic DNA from 63 AUST-02 isolates (including 37 isolates of the AUST-02 strain sub-

399 type, M3L7; PRJEB14781, PRJEB14771, PRJEB21755) and 51 AUST-06 isolates

400 (PRJEB35026, PRJNA325248) were utilised (Freschi et al., 2019, Sherrard et al., 2017, Tai

401 et al., 2015a, Wee et al., 2018). These isolates originated from the sputum of 50 participants

- 402 (10 aged <18-years) attending three CF centres in Brisbane (see Table SII for further details).
- 403 One isolate was sequenced from 32 participants with a median of three (range, 2-17) isolates
- 404 sequenced from the remaining 18 participants. Two participants had both strains identified

405	contemporaneo	ously (Pa	atient-37 & Pa	atient-38). V	Whole §	genome sequ	uences	were eva	luated for
406	contamination	and qua	lity filtered us	sing Nesoni	i clip (v0.128) (htt	ps://gith	ub.com/	Victorian-
407	Bioinformatics	s-Consor	tium/nesoni).	Genomes	were	assembled	using	Velvet	(v1.2.10)
408	(Zerbino	&	Birney,	2008)	and	Velve	etOptim	iser	(v2.2.5)
409	(https://github.	.com/tsee	emann/Velvet	Optimiser).	Contig	s were reor	rdered	with PA	O1 as the
410	reference using	g Mauve	(v2.4.0) (Dar	ling, Mau e	et al., 20	010). Assem	ıblies w	ere anno	tated with
411	Prokka (v1.10)) with the	e PAO1 genon	ne as the pri	imary s	ource of ann	notation	(Seemar	nn, 2014).
412									

413 Due to the absence of a closely related complete reference genome (less than 20,000 single 414 nucleotide polymorphisms [SNPs]) to AUST-02 and AUST-06 lineages, we first used Parsnp 415 to align the AUST-02 and AUST-06 isolates to PAO1 to determine the approximate position 416 of the root of each lineage (Treangen, Ondov et al., 2014). A multiple genome alignment was 417 then calculated with only genomes from each shared strain. Alignments were filtered for 418 recombination using Gubbins (v2.3.1) and Maximum-Likelihood phylogenies were 419 constructed with IQTREE (v1.6.6) with 1000 bootstrap replicates (Croucher, Page et al., 420 2014, Nguyen, Schmidt et al., 2015).

421

422 Identification of *oprD* variants

Gene sequences of *oprD* from the 63 AUST-02 and 51 AUST-06 isolates were then obtained from the whole genome sequences. Sequence similarity to *oprD* from PAO1 (PA0958; 1332base pairs [bp]) was determined using blastn requiring \geq 50% of the query sequence to be present. The AUST-02 and AUST-06 *oprD* variants were then aligned using TranslatorX and Mafft (Abascal, Zardoya et al., 2010, Katoh & Standley, 2013). Relationships between the different *oprD* variants were visualised using the Neighbour-Joining algorithm implemented in Jalview (v2.10.4b1) (Waterhouse, Procter et al., 2009).

430 **Etest® susceptibility testing**

Isolates were inoculated onto Mueller-Hinton Agar and minimum inhibitory concentrations
(MICs) were obtained by Etest[®] (BioMérieux) according to the manufacturer's instructions.
Isolates were categorised as susceptible, intermediate or resistant (CLSI, 2018). The *P. aeruginosa* ATCC 27853 strain was used for quality control.

435

436 Site-directed mutagenesis

Bacterial strains and plasmids are described in Table SIII. Strains were cultured in Luria-Bertani broth at 37°C with shaking at 200rpm and supplemented with antibiotics when appropriate: kanamycin 50µg/mL or streptomycin 50µg/mL or 2000µg/mL (Astral Scientific). Polymerase chain reaction (PCR) assays were performed in an Applied Biosystems Veriti Thermal cycler with oligonucleotide primer sequences shown in Table SIV.

443

444 Mutants of *P. aeruginosa* PAO1 (Klockgether, Munder et al., 2010), were constructed by 445 site-directed mutagenesis of chromosomally encoded oprD, performed essentially as 446 described by Muhl and Filloux (Muhl & Filloux, 2014); specific details and minor variations 447 are outlined in the supporting information. Plasmid constructs with the SNPs of interest 448 (oprD c.526G>T, p.E176X; oprD c.748C>T, p.Q250X; oprD c.956C>A, p.S319X) were 449 constructed using plasmid pMRS101 (Sarker & Cornelis, 1997). The pMRS101 constructs 450 were mobilised from *Escherichia coli* CC118 λ pir into PAO1 using a triparental mating with 451 *E. coli* DH5 α harbouring the helper plasmid pRK2013 (Ditta, Stanfield et al., 1980) 452 according to the method of Sana et al (Sana, Laubier et al., 2014). A single homologous 453 recombination event was selected using streptomycin and a second homologous 454 recombination event was counter selected with 5% sucrose was performed using the method

described by Muhl and Filloux (Muhl & Filloux, 2014). The disc diffusion method (Thermo
Fisher Scientific) was employed to detect resistance to imipenem as a screen for potential
isogenic mutants. The presence of the SNPs in the genome of putative PAO1 mutants was
confirmed by PCR and DNA sequencing. The confirmed isogenic mutants were named:
PAO1-OprD^{E176X}, PAO1-OprD^{Q250X}, and PAO1-OprD^{S319X}.

460

461 Complementation of the PAO1-Opr D^{E176X} , PAO1-Opr D^{Q250X} , and PAO1-Opr D^{S319X} mutants 462 was performed using a pMRS101 plasmid construct with the wild-type *oprD* gene encoded 463 and the same methodologies employed to generate the original mutations. Complemented 464 mutants were named: PAO1-Opr D^{E176C} , PAO1-Opr D^{Q250C} and PAO1-Opr D^{S319C} .

465

466 Proteomic analysis of OprD from P. aeruginosa PAO1

467 A detailed description of all steps is provided in the supporting information. Briefly, C18 468 reverse phase chromatography was performed on whole protein preparations from the cell 469 pellets of PAO1, each isogenic mutant and its complement. Data-dependent acquisition 470 (DDA) runs were performed to identify sequence coverage of the OprD protein and generate 471 a spectral library and scheduled targeted PRM runs for targeted verification. Protein 472 identification was performed using MaxQuant (v1.6.2.6) (Cox & Mann, 2008, Cox, 473 Neuhauser et al., 2011). The results were visualised using Perseus (Tyanova, Temu et al., 474 2016). Skyline was used to generate scheduled targeted methods and select precursor-product 475 pairs (transitions) from the DDA dataset (MacLean, Tomazela et al., 2010, Schilling, Rardin 476 et al., 2012).

478

479

480 **Growth curve analysis**

As an indicator of *in vitro* fitness, the growth of each isogenic mutant was compared to that of PAO1. 200 μ L of a culture containing 1.0–1.5 x 10⁶ colony-forming units/mL in Luria-Bertani Broth was transferred to a 96-well microtitre plate in triplicate and incubated with shaking at 37°C for 20-hours. Growth was monitored (OD_{620nm}) using a Biotek Powerwave plate reader.

486

487 Variant-specific PCR

488 Variant-specific PCR assays were designed to rapidly screen a collection of AUST-02 489 (n=569) and AUST-06 (n=321) isolates for target oprD SNPs. These isolates originated from 490 sputum of 149 participants (median [range], 6 [1-19] isolates/person). Primer sequences are 491 described in Table SV. Each reaction mix contained 10µL Platinum SYBR Green qPCR 492 superMix-UDG (Invitrogen), 1µL each of 10µM sense and anti-sense primer pairs (Sigma-493 Aldrich), 2µL of isolate DNA (Anuj, Whiley et al., 2009) and nuclease-free water (Qiagen) 494 made up to a total volume of 20µL. The PCR amplification was performed on a Rotor-Gene 495 Q instrument (QIAGEN Pty Ltd) as described in the supporting information.

496

497 Clinical characteristics

498 Data were retrieved from medical records, the referring CF centre and/or the Australian CF 499 Data Registry. Age, gender, height, weight, spirometry with percent predicted calculated 500 using the Global Lung Function Initiative equations (Quanjer, Hall et al., 2012), co-501 morbidities, long-term treatments and infection status with *P. aeruginosa* (Lee, Brownlee et

al., 2003, Ramsay, Sandhu et al., 2017) were obtained. Cystic fibrosis transmembrane conductance regulator (CFTR) function was recorded from the genotype as residual, minimal or non-classified (Green, McDougal et al., 2010). Data on patients' hospitalisations in the previous year were collected. The date of death or lung transplantation was recorded, where applicable.

507 Data analyses

508 Statistical analyses were generated using IBM SPSS v22. MICs were compared using a 509 Mann-Whitney U test or a Kruskal-Wallis test with the Bonferroni adjustment applied. 510 Categorical data were compared using Pearson's Chi-squared test. Based on the outcome of 511 the variant-specific PCRs, participants were categorised as either cases (PCR positive for a 512 target oprD SNP) or control subjects (PCR negative) and clinical characteristics of each 513 group were described using descriptive statistics. For cases, data relate to the date of first 514 detection of a strain that tested positive for a target SNP. For controls, data relate to the date 515 of first detection of AUST-02 or AUST-06. Participants (n=9) with only one isolate were 516 reported according to that PCR result. Potential predictors of being a case were identified by 517 univariate analysis as having $p \le 0.15$ and examined in a multivariable logistic regression 518 model using backwards stepwise selection; variables expected to affect risk (age and type of 519 shared strain infection) were retained to control for any potential confounding effects. Prior 520 to their inclusion variables were checked for collinearity. Adjusted odds and 95% confidence 521 intervals are reported. Cox regression was used to assess the association between being a case 522 with time to lung transplantation or death. For patients who had not had a transplant and were 523 still alive, time was censored on the 31st August 2017. The Cox regression model also 524 included age, gender and the type of shared strain infection. The hazard ratio and 95% 525 confidence interval are reported.

527 ACKNOWLEDGEMENTS

We thank the Proteomics Facility of QIMR Berghofer Medical Research Institute, and the advice of Emma Norris, Dr. Madeleine Headlam, and Dr. Harsha Gowda relating to the proteomics aspect of this work is greatly appreciated. We also thank Chrissie Schot and Samantha Webster (QIMR Berghofer Medical Research Institute) for their contribution to the site-directed mutagenesis and variant-specific PCRs aspects of this study, respectively.

533

534 FUNDING

535 Work funded by IMPACT Philanthropy Application Program (grant IPAP2016/01112), UQ-

QIMRB (Australian Infectious Disease Grant initiative), The National Health and Medical
Research Council (NHMRC) Project (grant 455919), The Children's Health Foundation
Queensland (grant 50007) and The Health Innovation, Investment and Research Office of
Queensland Health. TJK. acknowledges NHMRC Early Career (GNT10884488) and ERSEU RESPIRE2 Marie Sklodowska-Curie Postdoctoral Research (#4571-2013) Fellowship
support.

542

543 AUTHOR CONTRIBUTIONS

LJS, BAW, TJK and SCB conceived the study and wrote the first draft of the manuscript. LJS, BAW, CD, KAR, KAD, EB, CEW, KG, HES, DMW, SAB, TJK and SCB designed/performed the experiments, performed analysis, interpreted the results and/or contributed data for this work. All authors contributed to and approved the final version of the manuscript.

549

550 CONFLICT OF INTEREST

551 The authors declare that they have no conflict of interest.

552

553 THE PAPER EXPLAINED

554

555 **Problem**

556 *Pseudomonas aeruginosa* is the most important pathogen chronically infecting the lungs of 557 people with cystic fibrosis (CF) and cross-infection of strains (shared strains) can occur. P. 558 aeruginosa is known to develop antimicrobial resistance (AMR) including to carbapenem 559 antibiotics, which are often reserved for people with the most advanced disease. Despite 560 reports of reduced susceptibility of CF P. aeruginosa to carbapenems, the underlying 561 resistance mechanisms are less clear. Studies have also shown that as *P. aeruginosa* adapts to 562 persist in the CF lungs during long-term antibiotic treatment, certain genes are more prone to 563 mutation than others. However, there is limited information on whether mutations in AMR-564 related genes (e.g. oprD) are characteristic of particular shared strain genotypes or whether 565 novel variants are generally observed in individual patient isolates. Importantly, there is a 566 paucity of data on whether the chromosomal mutations observed are of any clinical 567 relevance.

568

569 **Results**

In this study, we performed a detailed analysis of the *oprD* gene, which is hypothesised to play an important role in adaptation of *P. aeruginosa* to the CF lungs, and AMR in two shared strains that are prevalent in our patient population. We identified commonly occurring *oprD* allelic variants in isolates from multiple patients, that were unique to specific sharedstrain lineages suggesting that successful *oprD* alleles emerge and persist in these shared strain populations. By constructing and characterising *P. aeruginosa oprD* mutants, we show

that these variants are likely to contribute to reduced carbapenem susceptibility without compromising *in vitro* fitness. We also identified a subset of people infected with the shared strains with poorer clinical outcomes, including an increased hazard rate of death or lung transplantation, based on detection of specific *oprD* variants.

580

581 Impact

582 Our findings emphasise the role of *oprD* mutations in carbapenem resistance in the setting of

583 P. aeruginosa lung infections in CF. Further our findings highlight the importance of

584 thorough investigations of genes under strong antimicrobial selection pressure to help

585 improve our understanding of (1) chronic-stage *P. aeruginosa* adaptions that may contribute

to strain transmissibility and (2) the greater adverse patient outcomes observed in some

587 people with CF despite infection with clonally-related strains.

589 **REFERENCES**

590 Abascal F, Zardoya R, Telford MJ (2010) TranslatorX: multiple alignment of nucleotide 591 sequences guided by amino acid translations. *Nucleic Acids Res* 38: W7-13

Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP (2009)
Identification of *Pseudomonas aeruginosa* by a duplex real-time polymerase chain reaction
assay targeting the *ecfX* and the *gyrB* genes. *Diagn Microbiol Infect Dis* 63: 127-31

- 595 Chalhoub H, Saenz Y, Rodriguez-Villalobos H, Denis O, Kahl BC, Tulkens PM, Van
 596 Bambeke F (2016) High-level resistance to meropenem in clinical isolates of *Pseudomonas*597 *aeruginosa* in the absence of carbapenemases: role of active efflux and porin alterations. *Int J*598 Antimicrob Agents 48: 740-743
- 599 Choi Y, Sims GE, Murphy S, Miller JR, Chan AP (2012) Predicting the functional effect of 600 amino acid substitutions and indels. *PLoS One* 7: e46688
- 601 CLSI (2018) Performance Standards for Antimicrobial Susceptibility Testing. CLSI
 602 supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA
- Courtois N, Caspar Y, Maurin M (2018) Phenotypic and genetic resistance traits of
 Pseudomonas aeruginosa strains infecting cystic fibrosis patients: A French cohort study. Int
 J Antimicrob Agents 52: 358-364
- Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized
 ppb-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol* 26:
 1367
- Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M (2011) Andromeda: a
 peptide search engine integrated into the MaxQuant environment. *J Proteome Res* 10: 1794805
- Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, Parkhill J, Harris SR
 (2014) Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome
 sequences using Gubbins. *Nucleic Acids Res* 43: e15-e15
- 615 Darling AE, Mau B, Perna NT (2010) progressiveMauve: multiple genome alignment with 616 gene gain, loss and rearrangement. *PLoS One* 5: e11147
- 617 Dettman JR, Rodrigue N, Aaron SD, Kassen R (2013) Evolutionary genomics of epidemic
- and nonepidemic strains of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 110: 21065 70
- Diaz Caballero J, Clark ST, Coburn B, Zhang Y, Wang PW, Donaldson SL, Tullis DE, Yau
 YC, Waters VJ, Hwang DM, Guttman DS (2015) Selective Sweeps and Parallel
 Pathoadaptation Drive *Pseudomonas aeruginosa* Evolution in the Cystic Fibrosis Lung. *MBio*6: e00981-15
- Ditta G, Stanfield S, Corbin D, Helinski DR (1980) Broad host range DNA cloning system for gram-negative bacteria: construction of a gene bank of *Rhizobium meliloti*. *Proc Natl*
- 626 Acad Sci U S A 77: 7347-51

Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda G, Waltz D,
Wainwright CE, Vx T, groups Ts (2016) Efficacy and safety of lumacaftor/ivacaftor
combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by
pulmonary function subgroup: a pooled analysis. *Lancet Respir Med* 4: 617-626

Epp SF, Kohler T, Plesiat P, Michea-Hamzehpour M, Frey J, Pechere JC (2001) C-terminal
 region of *Pseudomonas aeruginosa* outer membrane porin OprD modulates susceptibility to

- 633 meropenem. Antimicrob Agents Chemother 45: 1780-7
- 634 Fluit AC, Rentenaar RJ, Ekkelenkamp MB, Severs TT, Mavinkurve-Groothuis AMC, Rogers
- 635 MRC, Bruin MCA, Wolfs TFW (2019) Fatal carbapenem resistance development in
- 636 Pseudomonas aeruginosa under meropenem monotherapy, caused by mutations in the OprD
- 637 outer membrane porin. *Pediatr Infect Dis J* 38: 398-399

Freschi L, Vincent AT, Jeukens J, Emond-Rheault JG, Kukavica-Ibrulj I, Dupont MJ,
Charette SJ, Boyle B, Levesque RC (2019) The *Pseudomonas aeruginosa* pan-genome
provides new insights on its population structure, horizontal gene transfer, and pathogenicity. *Genome Biol Evol* 11: 109-120

642

643 Green DM, McDougal KE, Blackman SM, Sosnay PR, Henderson LB, Naughton KM, 644 Collaco JM, Cutting GR (2010) Mutations that permit residual CFTR function delay 645 acquisition of multiple respiratory pathogens in CF patients. *Respir Res* 11: 140

Greipel L, Fischer S, Klockgether J, Dorda M, Mielke S, Wiehlmann L, Cramer N, Tummler
B (2016) Molecular epidemiology of mutations in antimicrobial resistance loci of *Pseudomonas aeruginosa* isolates from airways of cystic fibrosis patients. *Antimicrob Agents Chemother* 60: 6726-6734

Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI (2009) *Pseudomonas aeruginosa lasR* mutants are associated with cystic fibrosis lung disease

652 progression. J Cyst Fibros 8: 66-70

Huang H, Jeanteur D, Pattus F, Hancock RE (1995) Membrane topology and site-specific
mutagenesis of *Pseudomonas aeruginosa* porin OprD. *Mol Microbiol* 16: 931-41

- Jaillard M, van Belkum A, Cady KC, Creely D, Shortridge D, Blanc B, Barbu EM, Dunne
 WM, Jr., Zambardi G, Enright M, Mugnier N, Le Priol C, Schicklin S, Guigon G, Veyrieras
 JB (2017) Correlation between phenotypic antibiotic susceptibility and the resistome in
- 658 Pseudomonas aeruginosa. Int J Antimicrob Agents 50: 210-218
- Katoh K, Standley DM (2013) MAFFT multiple sequence alignment software version 7:
 improvements in performance and usability. *Mol Biol Evol* 30: 772-80

Kidd TJ, Ramsay KA, Hu H, Marks GB, Wainwright CE, Bye PT, Elkins MR, Robinson PJ,
Rose BR, Wilson JW, Grimwood K, Bell SC, Group ACI (2013) Shared *Pseudomonas aeruginosa* genotypes are common in Australian cystic fibrosis centres. *Eur Respir J* 41:
1091-100

- 665 Kidd TJ, Ramsay KA, Vidmar S, Carlin JB, Bell SC, Wainwright CE, Grimwood K,
- Investigators AS (2015) *Pseudomonas aeruginosa* genotypes acquired by children with cystic
 fibrosis by age 5-years. *J Cyst Fibros* 14: 361-9

- 668 Klockgether J, Munder A, Neugebauer J, Davenport CF, Stanke F, Larbig KD, Heeb S,
- 669 Schock U, Pohl TM, Wiehlmann L, Tummler B (2010) Genome diversity of *Pseudomonas* 670 *aeruginosa* PAO1 laboratory strains. *J Bacteriol* 192: 1113-21

Knibbs LD, Johnson GR, Kidd TJ, Cheney J, Grimwood K, Kattenbelt JA, O'Rourke PK,
Ramsay KA, Sly PD, Wainwright CE, Wood ME, Morawska L, Bell SC (2014) Viability of *Pseudomonas aeruginosa* in cough aerosols generated by persons with cystic fibrosis. *Thorax*69: 740-5

- Kos VN, Deraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, Gardner
 H (2015) The resistome of *Pseudomonas aeruginosa* in relationship to phenotypic
 susceptibility. *Antimicrob Agents Chemother* 59: 427-36
- Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM (2003) Evaluation of a new
 definition for chronic *Pseudomonas aeruginosa* infection in cystic fibrosis patients. *J Cyst Fibros* 2: 29-34
- Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM (2012) Structure and function of OprD
 protein in *Pseudomonas aeruginosa*: from antibiotic resistance to novel therapies. *Int J Med Microbiol* 302: 63-8
- Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, Collins J, Rock MJ, Splaingard ML (2005) Longitudinal development of mucoid *Pseudomonas aeruginosa* infection and lung disease progression in children with cystic fibrosis. *JAMA* 293: 581-8
- Llanes C, Pourcel C, Richardot C, Plesiat P, Fichant G, Cavallo JD, Merens A, Group GS
 (2013) Diversity of beta-lactam resistance mechanisms in cystic fibrosis isolates of *Pseudomonas aeruginosa*: a French multicentre study. J Antimicrob Chemother 68: 1763-71
- MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb
 DL, Liebler DC, MacCoss MJ (2010) Skyline: an open source document editor for creating
 and analyzing targeted proteomics experiments. *Bioinformatics* 26: 966-8
- and undyzing targeted protoonnes experiments. Diongormanes 20. 900 0
- MacLean RC, San Millan A (2019) The evolution of antibiotic resistance. *Science* 365: 10821083
- Marvig RL, Dolce D, Sommer LM, Petersen B, Ciofu O, Campana S, Molin S, Taccetti G,
 Johansen HK (2015a) Within-host microevolution of *Pseudomonas aeruginosa* in Italian
 cystic fibrosis patients. *BMC Microbiol* 15: 218
- 698 Marvig RL, Johansen HK, Molin S, Jelsbak L (2013) Genome analysis of a transmissible 699 lineage of *Pseudomonas aeruginosa* reveals pathoadaptive mutations and distinct 700 evolutionary paths of hypermutators. *PLoS Genet* 9: e1003741
- Marvig RL, Sommer LM, Molin S, Johansen HK (2015b) Convergent evolution and
 adaptation of *Pseudomonas aeruginosa* within patients with cystic fibrosis. *Nat Genet* 47: 5764
- Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, Retsch-Bogart
 GZ, Morgan W, Wolter DJ, Pope CE, Houston LS, Kulasekara BR, Khan U, Burns JL, Miller
 SI, Hoffman LR (2014) *Pseudomonas aeruginosa in vitro* phenotypes distinguish cystic
- fibrosis infection stages and outcomes. Am J Respir Crit Care Med 190: 289-97

- 708 Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, Walshaw MJ, Brockhurst MA,
- 709 Winstanley C (2011) Pseudomonas aeruginosa population diversity and turnover in cystic 710
- fibrosis chronic infections. Am J Respir Crit Care Med 183: 1674-9
- 711 Muhl D, Filloux A (2014) Site-directed mutagenesis and gene deletion using reverse 712 genetics. In Pseudomonas Methods and Protocols, pp 521-539. Springer
- 713 Murray TS, Egan M, Kazmierczak BI (2007) Pseudomonas aeruginosa chronic colonization 714 in cystic fibrosis patients. Curr Opin Pediatr 19: 83-8
- 715 Mustafa MH, Chalhoub H, Denis O, Deplano A, Vergison A, Rodriguez-Villalobos H, 716 Tunney MM, Elborn JS, Kahl BC, Traore H, Vanderbist F, Tulkens PM, Van Bambeke F
- 717 (2016) Antimicrobial susceptibility of *Pseudomonas aeruginosa* isolated from cystic fibrosis
- 718 patients in Northern Europe. Antimicrob Agents Chemother 60: 6735-6741
- 719 Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ (2015) IQ-TREE: a fast and effective
- 720 stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol 32: 268-
- 721 74
- 722 O'Carroll MR, Syrmis MW, Wainwright CE, Greer RM, Mitchell P, Coulter C, Sloots TP, 723 Nissen MD, Bell SC (2004) Clonal strains of *Pseudomonas aeruginosa* in paediatric and
- 724 adult cystic fibrosis units. Eur Respir J 24: 101-6
- 725 Ocampo-Sosa AA, Cabot G, Rodriguez C, Roman E, Tubau F, Macia MD, Moya B,
- 726 Zamorano L, Suarez C, Pena C, Dominguez MA, Moncalian G, Oliver A, Martinez-Martinez
- 727 L, Spanish Network for Research in Infectious D (2012) Alterations of OprD in carbapenem-
- 728 intermediate and -susceptible strains of *Pseudomonas aeruginosa* isolated from patients with
- 729 bacteremia in a Spanish multicenter study. Antimicrob Agents Chemother 56: 1703-13
- 730 Ojeniyi B, Frederiksen B, Høiby N (2000) Pseudomonas aeruginosa cross infection among 731 patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 29: 177-181
- 732 Parkins MD, Somayaji R, Waters VJ (2018) Epidemiology, biology, and impact of clonal 733 Pseudomonas aeruginosa infections in cystic fibrosis. Clin Microbiol Rev 31: e00019-18
- 734 Pezzulo AA, Tang XX, Hoegger MJ, Abou Alaiwa MH, Ramachandran S, Moninger TO, 735 Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M, Banfi B, Horswill AR, Stoltz 736 DA, McCray PB, Jr., Welsh MJ, Zabner J (2012) Reduced airway surface pH impairs 737 bacterial killing in the porcine cystic fibrosis lung. Nature 487: 109-13
- 738 Quanjer PH, Hall GL, Stanojevic S, Cole TJ, Stocks J, Global Lungs I (2012) Age- and 739 height-based prediction bias in spirometry reference equations. Eur Respir J 40: 190-7
- 740 Ramsay KA, Bell SC, Grimwood K, Wainwright CE, Kidd TJ (2016) Emergence of a shared 741 Pseudomonas aeruginosa strain within an adult cystic fibrosis centre. Journal of Cystic 742 Fibrosis 15: S70
- 743 Ramsay KA, Sandhu H, Geake JB, Ballard E, O'Rourke P, Wainwright CE, Reid DW, Kidd
- 744 TJ, Bell SC (2017) The changing prevalence of pulmonary infection in adults with cystic
- 745 fibrosis: A longitudinal analysis. J Cyst Fibros 16: 70-77

- Rodriguez-Martinez JM, Poirel L, Nordmann P (2009) Molecular epidemiology and mechanisms of carbapenem resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents*
- 748 Chemother 53: 4783-8
- Sana T, Laubier A, Bleves S (2014) Gene Transfer: Conjugation. In *Pseudomonas Methods and Protocols*, Filoux A, Ramos J (eds) New York, NY: Humana Press
- Sarker MR, Cornelis GR (1997) An improved version of suicide vector pKNG101 for gene
 replacement in gram-negative bacteria. *Mol Microbiol* 23: 410-1
- Schilling B, Rardin MJ, MacLean BX, Zawadzka AM, Frewen BE, Cusack MP, Sorensen
 DJ, Bereman MS, Jing E, Wu CC, Verdin E, Kahn CR, Maccoss MJ, Gibson BW (2012)
 Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion
 chromatograms in skyline: application to protein acetylation and phosphorylation. *Mol Cell Proteomics* 11: 202-14
- 758 Seemann T (2014) Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30: 2068-9
- 759 Sherrard LJ, Tai AS, Wee BA, Ramsay KA, Kidd TJ, Ben Zakour NL, Whiley DM, Beatson
- 760 SA, Bell SC (2017) Within-host whole genome analysis of an antibiotic resistant
- 761 *Pseudomonas aeruginosa* strain sub-type in cystic fibrosis. *PLoS One* 12: e0172179
- 762 Skurnik D, Roux D, Cattoir V, Danilchanka O, Lu X, Yoder-Himes DR, Han K, Guillard T,
- Jiang D, Gaultier C, Guerin F, Aschard H, Leclercq R, Mekalanos JJ, Lory S, Pier GB (2013)
- 764 Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa
- revealed through high-throughput sequencing. *Proc Natl Acad Sci U S A* 110: 20747-52
- 766 Smith DJ, Ramsay KA, Yerkovich ST, Reid DW, Wainwright CE, Grimwood K, Bell SC,
- Kidd TJ (2016) *Pseudomonas aeruginosa* antibiotic resistance in Australian cystic fibrosis
 centres. *Respirology* 21: 329-37
- Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI,
 Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV (2006) Genetic
 adaptation by *Pseudomonas aeruginosa* to the airways of cystic fibrosis patients. *Proc Natl*
- 772 Acad Sci USA 103: 8487-92
- Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn
 JS, Bell SC, Flume PA, VanDevanter DR, Antimicrobial Resistance in Cystic Fibrosis
 InternationalWorking G (2019) Antimicrobial susceptibility testing (AST) and associated
 clinical outcomes in individuals with cystic fibrosis: A systematic review. *J Cyst Fibros* 18:
 236-243
- Strateva T, Yordanov D (2009) *Pseudomonas aeruginosa*-a phenomenon of bacterial
 resistance. *J Med Microbiol* 58: 1133-1148
- Syrmis MW, Kidd TJ, Moser RJ, Ramsay KA, Gibson KM, Anuj S, Bell SC, Wainwright
 CE, Grimwood K, Nissen M, Sloots TP, Whiley DM (2014) A comparison of two
 informative SNP-based strategies for typing *Pseudomonas aeruginosa* isolates from patients
 with cystic fibrosis. *BMC Infect Dis* 14: 307
- Tai AS, Bell SC, Kidd TJ, Trembizki E, Buckley C, Ramsay KA, David M, Wainwright CE,
 Grimwood K, Whiley DM (2015a) Genotypic dversity within a single *Pseudomonas*

- *aeruginosa* strain commonly shared by Australian patients with cystic fibrosis. *PLoS One* 10:
 e0144022
- Tai AS, Kidd TJ, Whiley DM, Ramsay KA, Buckley C, Bell SC, Group ACI (2015b)
 Molecular surveillance for carbapenemase genes in carbapenem-resistant *Pseudomonas aeruginosa* in Australian patients with cystic fibrosis. *Pathology* 47: 156-60
- Tai AS, Sherrard LJ, Kidd TJ, Ramsay KA, Buckley C, Syrmis M, Grimwood K, Bell SC,
 Whiley DM (2017) Antibiotic perturbation of mixed-strain *Pseudomonas aeruginosa*infection in patients with cystic fibrosis. *BMC Pulm Med* 17: 138
- Treangen TJ, Ondov BD, Koren S, Phillippy AM (2014) The Harvest suite for rapid core genome alignment and visualization of thousands of intraspecific microbial genomes.
 Genome Biol 15: 524
- Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J (2016) The
 Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat Methods* 13: 731-40
- Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ (2009) Jalview Version 2—a
 multiple sequence alignment editor and analysis workbench. *Bioinformatics* 25: 1189-1191
- Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn
 JS, Flume PA, VanDevanter DR, Gilligan P, Antimicrobial Resistance International Working
 Group in Cystic F (2019) Reconciling antimicrobial susceptibility testing and clinical
 response in antimicrobial treatment of chronic cystic fibrosis lung infections. *Clin Infect Dis*
- Wee BA, Tai AS, Sherrard LJ, Ben Zakour NL, Hanks KR, Kidd TJ, Ramsay KA, Lamont I,
 Whiley DM, Bell SC, Beatson SA (2018) Whole genome sequencing reveals the emergence
 of a *Pseudomonas aeruginosa* shared strain sub-lineage among patients treated within a
 single cystic fibrosis centre. *BMC Genomics* 19: 644
- Williams D, Evans B, Haldenby S, Walshaw MJ, Brockhurst MA, Winstanley C, Paterson S
 (2015) Divergent, coexisting *Pseudomonas aeruginosa* lineages in chronic cystic fibrosis
 lung infections. *Am J Respir Crit Care Med* 191: 775-85
- 813 Winsor GL, Griffiths EJ, Lo R, Dhillon BK, Shay JA, Brinkman FS (2016) Enhanced 814 annotations and features for comparing thousands of *Pseudomonas* genomes in the 815 *Pseudomonas* genome database. *Nucleic Acids Res* 44: D646-53
- Yoon EJ, Kim D, Lee H, Lee HS, Shin JH, Park YS, Kim YA, Shin JH, Shin KS, Uh Y,
 Jeong SH (2019) Mortality dynamics of *Pseudomonas aeruginosa* bloodstream infections
 and the influence of defective OprD on mortality: prospective observational study. J
 Antimicrob Chemother 74: 2774-2783
- Zerbino DR, Birney E (2008) Velvet: algorithms for de novo short read assembly using de
 Bruijn graphs. *Genome Res* 18: 821-9
- 822

823 FIGURE LEGENDS

824 Fig 1 A Phylogenetic relationship of AUST-02 and AUST-06 oprD variants. Amino acid 825 substitutions shown in parentheses. The Neighbour-Joining algorithm implemented in 826 Jalview was used to visualise relationships between the different variants. The coloured bars 827 on the right-hand side indicate the oprD variant categories used to compare AMR results 828 (purple, target SNP i.e. 1-bp substitution leading to nonsense mutation; grey, wild-type 829 sequence; yellow, indel mutation including disruption by IS). B Recombination-filtered, 830 Maximum-Likelihood core SNP phylogeny of AUST-02 (left) and AUST-06 (right) isolates 831 encoding the described *oprD* variants. Each variant is given a unique colour (note that one of 832 five isolates with the oprD c.438delG variant had acquired an additional oprD missense 833 mutation but are denoted by the same colour) in the first column and the patient number is 834 indicated in the 2^{nd} greyscale column. Branches supported by >80% bootstrap are indicated 835 by black circles, branches shown with dotted lines are not to scale. *Definitions*: IS, insertion 836 sequence; WT, wild-type.

837

Fig 2 Scheme showing how AUST-02 and AUST-06 isolates were screened for the target oprD SNPs. Participants were subsequently stratified according to PCR results: cases, positive for ≥ 1 *Pseudomonas aeruginosa* isolate with a target SNP; control subjects, isolates PCR negative (i.e. infected with isolates with non-target oprD variants).

843 FIGURES

- 844 Fig 1
- 845 A



B





onrD variant category	MIC	Percent	Percentage of isolates with					
op d antimizer high a cent*	Wite	(IIIg/ L)		indica	indicated susceptibility			
and antimicrobial agent.	Range	50%	90%	S	Ι	R		
<i>Target SNP (n=79)</i>								
Imipenem	12 to >32	>32	>32	0	0	100		
Meropenem	3 to >32	>32	>32	0	2.5	97.5		
Ticarcillin-clavulanate	2 to >256	>256	>256	8.9	2.5	88.6		
Ceftazidime	1 to >256	>256	>256	17.7	1.3	81.0		
Tobramycin	1 to >256	6	>256	40.5	29.1	30.4		
Colistin	0.125-1.5	0.5	1	100	0	0		
Indel (n=21)								
Imipenem	12 to >32	>32	>32	4.8	0	95.2		
Meropenem	0.75 to >32	>32	>32	14.3	9.5	76.2		
Ticarcillin-clavulanate	0.75 to >256	>256	>256	33.3	0	66.7		
Ceftazidime	0.25 to >256	4	>256	57.1	4.8	38.1		
Tobramycin	0.5 to >256	4	64	66.7	19.0	14.3		
Colistin	0.125-3	0.75	2	95.2	0	4.8		
Wild-type (n=14)								
Imipenem	0.125-6	1.5	3	78.6	14.3	7.1		
Meropenem	0.012-2	0.125	1.5	100	0	0		
Ticarcillin-clavulanate	0.125 to >256	4	>256	71.4	7.2	21.4		
Ceftazidime	0.064-16	1	16	85.7	14.3	0		
Tobramycin	0.25 to >256	4	>256	50.0	14.3	35.7		
Colistin	0.125-2	0.5	2	100	0	0		

853 **Table I** *In vitro* antimicrobial susceptibilities of isolates stratified by *oprD* variant category.

854 S, susceptible; I, intermediate; R, resistant

855 *oprD variant categories: Target SNP, one of three 1-bp substitutions leading to a nonsense mutation; indel, 1bp insertion or deletion leading to a shift in the reading frame or disruption by an insertion sequence; wild-type,

857 variant that is closest to the base of each *oprD* clade in the phylogeny (Fig 1A).

859 T	able II Sus	ceptibility	of PAO1	and mutant clones.
--------------	-------------	-------------	---------	--------------------

		Antibiotic MICs (mg/L); median (range)*							
PAO1 strain	oprD variant	Imipenem	Meropenem	Ticarcillin-	Ceftazidime	Tobramycin	Colistin		
				clavulanate					
Wild-type	Wild-type	1 (1-1.5)	0.38 (0.25-0.5)	12 (12-16)	0.75	0.5 (0.5-0.75)	1.5 (1.5-2)		
PAO1-OprD ^{E176X}	c.526G>T (p.E176X)	32 (16-32)	3 (2-4)	12 (12-16)	0.75 (0.5-0.75)	0.5 (0.5-0.75)	1.5		
PAO1-OprD ^{E176C}	Wild-type	1	0.25 (0.19-0.25)	12	0.5 (0.5-0.75)	0.5 (0.5-0.75)	1.5 (0.75-2)		
PAO1-OprD ^{Q250X}	c.748C>T (p.Q250X)	24 (12-32)	2 (1.5-3)	12	0.5 (0.5-0.75)	0.5	1.5		
PAO1-OprDQ250C	Wild-type	1	0.25 (0.25-0.5)	12 (12-16)	0.75 (0.5-0.75)	0.5 (0.38-0.5)	1.5		
PAO1-OprD ^{S319X}	c.956C→A (p.S319X)	32 (24-32)	1.5 (1.5-2)	16 (12-16)	0.5 (0.5-0.75)	0.38	1.5 (1.5-2)		
PAO1-OprD ^{S319C}	Wild-type	1 (0.75-1)	0.19 (0.19-0.25)	12 (8-12)	0.5 (0.5-0.75)	0.38 (0.38-0.5)	1.5		
*Biological replica	ates in triplicate v	vere performed.	If no range	shown, then	the MICs	of replicates	were identic		

861 **Table III Participant characteristics and their association with being a case.**

Characteristic	Number patients	Cases $(n=82)^{\ddagger}$	Control subjects $(n=66)^{\ddagger}$	Odds ratio (95% CI) [†]	р
Female; n (%)	148	37 (45.1)	28 (42.4)	1.07 (0.54-2.14)	0.80
CFTR function; n (%)	148				
- Minimal		70 (85.4)	57 (86.4)	1.03 (0.34-3.06)	1.00
- Residual		4 (4.9)	2 (3.0)	0.68 0.22-12.66)	0.60
- Non-classified		8 (9.7)	7 (10.6)	Reference group	
FEV ₁ % predicted, mean (sd)	144	49.0 (21.8)	64.2 (26.1)	0.97 (0.96-0.99)	<0.001
BMI, median (IQR)	148	19.4 (17.2-22.6)	21.4 (19.3-23.7)	0.92 (0.83-1.02)	0.11
Pancreatic insufficiency; n (%)	148	78 (95.1)	65 (98.5)	0.29 (0.03-2.82)	0.29
Cystic fibrosis-related diabetes; n (%)	148				
- D+FH		14 (17.1)	12 (18.2)	0.92 (0.38-2.22)	0.84
- IGT		8 (9.7)	5 (7.6)	1.25 (0.37-4.17)	0.72
- Normal GT		60 (73.2)	49 (74.2)	Reference group	
Liver disease; n (%)	148	9 (11.0)	7 (10.6)	1.06 (0.36-3.10)	0.90
Oral azithromycin; n (%)	147	73 (90.1)	54 (81.2)	1.98 (0.73-5.35)	0.18
Inhaled tobramycin; n (%)	147	71 (86.6)	51 (77.3)	2.13 (0.84-5.43)	0.11
Inhaled colistin; n (%)	147	46 (56.8)	24 (36.4)	2.48 (1.22-5.04)	0.010
Inhaled dornase alfa; n (%)	147	60 (74.1)	43 (65.2)	1.51 (0.72-3.16)	0.27
Number of days in hospital, median (IQR)	148	26.5 (10.8-51.8)	8.5 (0.0-16.8)	1.01 (1.00-1.03) [∥]	0.010

 $\frac{1}{2} \frac{1}{2} \frac{1}$

unknown function).

 $\frac{1}{2}$ Cases, tested positive for ≥ 1 isolate with a target *oprD* SNP (one case lacked clinical data and was excluded from the analysis); control subjects, tested negative for isolates with a target *oprD* SNP. Data collected relate to the date of first detection of AUST-02 and/or AUST-06 with a target SNP or to the date of first detection of AUST-02 and/or AUST-06 if always tested negative.

[†]All odds ratios presented are adjusted for age and shared strain infection (AUST-02, AUST-06 or mixed) due to their expected effects on odds of testing positive for an isolate with a target SNP in *oprD*; however, these potential confounders were never statistically significant in any of the models. Odds of being a case compared to being a control.

872	Bolded	text:	variables	included	in	the	multivariable	logistic	regression
								0	0